about
A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosisCo-administration of IL-1+IL-6+TNF-α with Mycobacterium tuberculosis infected macrophages vaccine induces better protective T cell memory than BCGEstablishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testingESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs.Reduced local growth and spread but preserved pathogenicity of a DeltapurC Mycobacterium tuberculosis auxotrophic mutant in gamma interferon receptor-deficient mice after aerosol infection.Diversity in functional organization of class I and class II biotin protein ligase.Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein.Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 ligand(hi) populationOral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosisDNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge.Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis.Pulmonary necrosis resulting from DNA vaccination against tuberculosis.Development of new vaccines and drugs for TB: limitations and potential strategic errorsNext generation: tuberculosis vaccines that elicit protective CD8+ T cellsImmunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapyTropical disease vaccines.How far have we reached in tuberculosis vaccine development?Animal models of tuberculosis: Guinea pigs.Drying a tuberculosis vaccine without freezingDeveloping an improved vaccine against tuberculosis.Tuberculosis vaccine development: research, regulatory and clinical strategies.The success and failure of BCG - implications for a novel tuberculosis vaccine.Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis.Vaccines for bovine tuberculosis: current views and future prospects.Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.The resumption of consumption -- a review on tuberculosis.Capture of heat-killed Mycobacterium bovis bacillus Calmette-Guérin by intelectin-1 deposited on cell surfaces.A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.The guinea pig as a model of infectious diseases.Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis.The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential.A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice.Farmed deer: A veterinary model for chronic mycobacterial diseases that is accessible, appropriate and cost-effective.Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response.Mycobacterial infection induces the secretion of high-mobility group box 1 protein.Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.Impact of methoxymycolic acid production by Mycobacterium bovis BCG vaccines.CHO expressed recombinant human lactoferrin as an adjuvant for BCG.
P2860
Q24554444-8BA30610-4E81-4010-B715-B199199424BEQ27437712-6B94734A-C95A-44CC-8BB8-7F23BC9FB735Q30227121-71B500EE-866B-44EB-A49E-3C516F46FC0FQ33330264-A06949C6-A25D-40D0-BFF0-911BB800ACDFQ33557025-0D876315-61B4-46EE-B51C-A0BFBA61518AQ33842024-9B0D6285-48BE-4B9E-83B7-5562D5948298Q34034191-7AE1831A-2CCB-466E-A5B7-F0B66CEB704AQ34111831-A705101C-FF1E-4C0F-AA08-5EF30E0294D9Q34122078-18F08137-28D7-4A58-886C-A6407FD26F17Q34124601-D15A7881-4049-48BB-9966-F80DD0302B07Q34581134-1BD2D3E8-BD32-468F-A3DE-2FC097847FE2Q34854656-1CA6F8D7-7B7D-4808-8533-00417EFF6FD5Q35065531-93B81A57-8E3A-45E1-96CE-5FD62A86FCC9Q35099708-B61FFFD7-D39F-4669-B61F-C9C40D3A9D90Q35124651-FD65BE82-B853-4A40-8918-54AEF7923723Q35193556-CCEB91BD-2F8A-4AC6-B57F-23CFA6B32AA8Q35592360-9850C794-A24F-4C48-B02A-0320772D80D0Q35663870-D31B38DB-4637-44E4-9E55-F65E09746132Q35669625-41BC8223-29D5-43D7-994D-052852E1022DQ35791774-202740AB-0918-44AD-B2AB-3DB28B5C46B7Q35873788-43428E62-77E3-4D66-B4CA-D72223E51D83Q36191944-7B80DB7D-70B5-45E1-B565-DCE6C1893DE1Q36228652-B5A74D73-ADE1-4C44-BEB1-F526A25F18B7Q36350586-7CEA2B66-B5B8-4FEE-A1E1-72B075929A2FQ36576750-3D592438-302E-46E7-906E-F5A4041A119EQ36679354-FB31F90F-A1E8-4D15-A945-B39EB70C173CQ37154042-003F1ECB-A362-45DB-A1E5-F84A07D22B81Q37188632-A9FF782F-08D0-4DF4-A450-1C04C6ADE4D3Q37251175-2D7671A4-D764-4362-A4A9-41E450B31A48Q37523075-75E310B9-2B7B-403A-967F-3210A34AD0EEQ37582822-437A4034-6852-4D87-96CF-0BDD3177AD19Q37623403-6BB65B8C-C3E8-4A66-8F84-BD255E6DC339Q37623702-EAB984B4-5049-496A-8E1D-1D482D479FADQ38181465-127A0E68-D64F-415E-9150-727A283CFB82Q38449050-67369847-A1DA-4F7D-A59B-04936EF4164AQ39705747-D4D81387-DE9F-48E1-B55B-54A714735609Q40004008-45A51796-52A9-4D0D-86D5-483AC9BED31EQ40308913-50D4F9AE-B800-4726-99FE-5F947D8EB8BBQ40563998-D6CD271A-7062-4833-BAD0-49255BD24935Q41028714-A3CB31CC-326D-473F-95C0-C4E9A80532CF
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tuberculosis vaccine development: recent progress.
@ast
Tuberculosis vaccine development: recent progress.
@en
Tuberculosis vaccine development: recent progress.
@nl
type
label
Tuberculosis vaccine development: recent progress.
@ast
Tuberculosis vaccine development: recent progress.
@en
Tuberculosis vaccine development: recent progress.
@nl
prefLabel
Tuberculosis vaccine development: recent progress.
@ast
Tuberculosis vaccine development: recent progress.
@en
Tuberculosis vaccine development: recent progress.
@nl
P2093
P1476
Tuberculosis vaccine development: recent progress.
@en
P2093
P304
P356
10.1016/S0966-842X(00)01949-1
P577
2001-03-01T00:00:00Z